These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 12853880)

  • 1. In vitro pharmacokinetic study of the novel anticancer agent E7070: red blood cell and plasma protein binding in human blood.
    Bongard HJ; Pluim D; Waardenburg RC; Ravic M; Beijnen JH; Schellens JH
    Anticancer Drugs; 2003 Jul; 14(6):405-10. PubMed ID: 12853880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic drug-drug interaction of the novel anticancer agent E7070 and acenocoumarol.
    van den Bongard HJ; Sparidans RW; Critchley DJ; Beijnen JH; Schellens JH
    Invest New Drugs; 2004 Apr; 22(2):151-8. PubMed ID: 14739663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An excretion balance and pharmacokinetic study of the novel anticancer agent E7070 in cancer patients.
    van sen Bongard HJ; Pluim D; Rosing H; Nan-Offeringa L; Schot M; Ravic M; Schellens JH; Beijnen JH
    Anticancer Drugs; 2002 Sep; 13(8):807-14. PubMed ID: 12394264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation.
    Van Kesteren Ch; Mathôt RA; Raymond E; Armand JP; Dittrich Ch; Dumez H; Roché H; Droz JP; Punt C; Ravic M; Wanders J; Beijnen JH; Fumoleau P; Schellens JH;
    J Clin Oncol; 2002 Oct; 20(19):4065-73. PubMed ID: 12351604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative determination of the novel anticancer drug E7070 (indisulam) and its metabolite (1,4-benzenedisulphonamide) in human plasma, urine and faeces by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
    Beumer JH; Rosing H; Hillebrand MJ; Nan-Offeringa LG; Foley K; Yule SM; Heck AJ; Schellens JH; Beijnen JH
    Rapid Commun Mass Spectrom; 2004; 18(23):2839-48. PubMed ID: 15517526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I and pharmacokinetic study of E7070, a chloroindolyl-sulfonamide anticancer agent, administered on a weekly schedule to patients with solid tumors.
    Dittrich C; Dumez H; Calvert H; Hanauske A; Faber M; Wanders J; Yule M; Ravic M; Fumoleau P
    Clin Cancer Res; 2003 Nov; 9(14):5195-204. PubMed ID: 14613999
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Saturable binding of indisulam to plasma proteins and distribution to human erythrocytes.
    Zandvliet AS; Copalu W; Schellens JH; Beijnen JH; Huitema AD
    Drug Metab Dispos; 2006 Jun; 34(6):1041-6. PubMed ID: 16565173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A semi-physiological population pharmacokinetic model describing the non-linear disposition of indisulam.
    Zandvliet AS; Schellens JH; Copalu W; Beijnen JH; Huitema AD
    J Pharmacokinet Pharmacodyn; 2006 Oct; 33(5):543-70. PubMed ID: 16946998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide).
    van Kesteren C; Mathôt RA; Raymond E; Armand JP; Fumoleau P; Punt C; Ravic M; Wanders J; Beijnen JH; Schellens JH;
    Br J Clin Pharmacol; 2002 Nov; 54(5):463-71. PubMed ID: 12445024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG).
    Terret C; Zanetta S; Roché H; Schellens JH; Faber MN; Wanders J; Ravic M; Droz JP;
    Eur J Cancer; 2003 May; 39(8):1097-104. PubMed ID: 12736109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KCN1, a novel synthetic sulfonamide anticancer agent: in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacology.
    Wang W; Ao L; Rayburn ER; Xu H; Zhang X; Zhang X; Nag SA; Wu X; Wang MH; Wang H; Van Meir EG; Zhang R
    PLoS One; 2012; 7(9):e44883. PubMed ID: 23028659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer.
    Raymond E; ten Bokkel Huinink WW; Taïeb J; Beijnen JH; Faivre S; Wanders J; Ravic M; Fumoleau P; Armand JP; Schellens JH;
    J Clin Oncol; 2002 Aug; 20(16):3508-21. PubMed ID: 12177112
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Binding of sulfonamides to erythrocyte proteins and possible drug-drug interaction.
    Matsumoto K; Miyazaki H; Fujii T; Amejima H; Furukawa H; Hashimoto M
    Chem Pharm Bull (Tokyo); 1989 Oct; 37(10):2807-10. PubMed ID: 2611942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. E7070: a novel synthetic sulfonamide targeting the cell cycle progression for the treatment of cancer.
    Van Kesteren C; Beijnen JH; Schellens JH
    Anticancer Drugs; 2002 Nov; 13(10):989-97. PubMed ID: 12439332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. E7070, a novel sulphonamide agent with potent antitumour activity in vitro and in vivo.
    Ozawa Y; Sugi NH; Nagasu T; Owa T; Watanabe T; Koyanagi N; Yoshino H; Kitoh K; Yoshimatsu K
    Eur J Cancer; 2001 Nov; 37(17):2275-82. PubMed ID: 11677118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. pSILAC method coupled with two complementary digestion approaches reveals PRPF39 as a new E7070-dependent DCAF15 substrate.
    Jia X; Pan L; Zhu M; Hu H; Zhai L; Liu J; Hu M; Liu B; Tan M
    J Proteomics; 2020 Jan; 210():103545. PubMed ID: 31626998
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticancer agent E7070 inhibits amino acid and uracil transport in fission yeast.
    Tsukahara K; Watanabe T; Hata-Sugi N; Yoshimatsu K; Okayama H; Nagasu T
    Mol Pharmacol; 2001 Dec; 60(6):1254-9. PubMed ID: 11723232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uptake and stereoselective binding of the enantiomers of MK-927, a potent carbonic anhydrase inhibitor, by human erythrocytes in vitro.
    Lin JH; Lin TH; Cheng H
    Pharm Res; 1992 Mar; 9(3):339-44. PubMed ID: 1614967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle inhibitor.
    Haddad RI; Weinstein LJ; Wieczorek TJ; Bhattacharya N; Raftopoulos H; Oster MW; Zhang X; Latham VM; Costello R; Faucher J; DeRosa C; Yule M; Miller LP; Loda M; Posner MR; Shapiro GI
    Clin Cancer Res; 2004 Jul; 10(14):4680-7. PubMed ID: 15269140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apparent stereoselectivity in propafenone uptake by human and rat erythrocytes.
    Mehvar R
    Biopharm Drug Dispos; 1991 May; 12(4):299-310. PubMed ID: 1873507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.